MD Anderson Cancer Center con la Colaboración del National Cancer Institute " Ha Empezado Ya " a Reclutar Pacientes del Ensayo de Fase I con la Combinación : Yondelis® ( de PharmaMar ) and Venetoclax (VENCLYXTO®) by AbbVie para el Tratamiento de Leucemia y Lymphoma .

Study NCT03884972
on Date: June 20, 2019 (v2) .


Brief Title : Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor .

Official Title : A Phase I/Ib Pilot Study of Combined Trabectedin and Venetoclax in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor .


Study Status 

Record Verification : June 2019 .

Overall Status : Recruiting .

Study Start : June 18, 2019 .

Primary Completion : April 9, 2020 [Anticipated] .

Study Completion : April 9, 2020 [Anticipated] .


Sposor/Collaborators

Sponsor : M.D. Anderson Cancer Center .

Responsible Party : Sponsor .

Collaborators : National Cancer Institute (NCI) .

Oversight

U.S. FDA-regulated Drug : Yes .

****************************

Más información sobre Venetoclax :